Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company specializing in nitric oxide therapy. Central to its offerings is the LungFit platform, an innovative nitric oxide generator and delivery system that uses patented Ionizer™ technology to produce unlimited, on-demand nitric oxide from ambient air, eliminating the need for traditional gas cylinders. The company’s product range includes LungFit PH for treating persistent pulmonary hypertension in newborns, LungFit PRO targeting viral lung infections like pneumonia and COVID-19, and LungFit GO for at-home treatment of nontuberculous mycobacteria infections. Beyond Air also develops therapeutics such as ultra-high concentration nitric oxide treatments for solid tumors and selective neuronal nitric oxide synthase inhibitors for neurological conditions including autism spectrum disorder. With a commitment to advancing respiratory and neurological healthcare, Beyond Air leverages its innovative technologies to expand treatment options across hospital and home settings, driven by a leadership team with deep clinical and scientific expertise.